Invivyd rallies amid interest in COVID therapy

[Coronavirus Mutant - Variation Omicron B.1.1.529]
peterschreiber.media

Shares of microcap biotech Invivyd (NASDAQ:IVVD [https://seekingalpha.com/symbol/IVVD]) jumped ~94% on Tuesday to reach the highest level in more than five months, a rally not seen since early this year as the company’s experimental COVID-19 therapy drew renewed investor interest.

The upsurge came after The Daily Beast reported on Monday that the Trump administration is planning to withdraw messenger RNA-based COVID-19 vaccines from the U.S. market within the coming months. [https://seekingalpha.com/news/4488784-trump-administration-could-ban-covid-19-jabs-within-months-dailybeast]

Earlier this month, Waltham, Massachusetts-headquartered Invivyd (NASDAQ:IVVD [https://seekingalpha.com/symbol/IVVD]) announced that it has aligned with the U.S. FDA on an expedited pathway that could allow it to receive full approval for its COVID-19 vaccine alternative VYD2311 in the U.S.

VYD2311 leverages the same antibody construct as Pemgarda (pemivibart), a monoclonal antibody marketed by IVVD under the FDA’s emergency use authorization for the prevention of COVID-19 in certain immunocompromised patients. [https://seekingalpha.com/news/4485867-invivyd-aligns-with-fda-on-fast-track-approval-path-for-covid-19-antibody-vyd2311]

Invivyd (NASDAQ:IVVD [https://seekingalpha.com/symbol/IVVD]) shares nearly tripled in value after the company announced data from a small Phase 1/2 trial for VYD2311 in February, highlighting its potential as an option for COVID prevention with a long dosing interval. [https://seekingalpha.com/pr/19988630-invivyd-announces-positive-phase-1-2-clinical-data-for-vyd2311-a-monoclonal-antibody-designed]

MORE ON INVIVYD

* Invivyd stock falls after pricing capital raise of $50M via securities offering [https://seekingalpha.com/news/4487743-invivyd-stock-falls-after-pricing-capital-raise-of-50m-via-securities-offering]
* Invivyd announces proposed public offering of common stock [https://seekingalpha.com/news/4487659-invivyd-announces-proposed-public-offering-of-common-stock]
* Seeking Alpha’s Quant Rating on Invivyd [https://seekingalpha.com/symbol/IVVD/ratings/quant-ratings]
* Historical earnings data for Invivyd [https://seekingalpha.com/symbol/IVVD/earnings]
* Financial information for Invivyd [https://seekingalpha.com/symbol/IVVD/income-statement]